The Future of 340B: What Hospitals and Rural Communities Need to Know

Major shifts to the 340B drug pricing program could be on the horizon, along with new regulations, legal battles and congressional scrutiny. In this Leadership Dialogue conversation, Tina Freese Decker, president and CEO of Corewell Health and 2025 AHA board chair, joins Aimee Kuhlman, vice president of advocacy grassroots and government relations at the AHA, and Paulette Davidson, president and CEO of Monument Health, to unpack what’s at stake. They explore potential regulatory changes for 340B, the lifeline it provides for rural hospitals, and how upcoming changes could alter the financial landscape for the hospitals that anchor their rural communities.